Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2005 3
2006 1
2007 1
2008 2
2010 2
2011 1
2012 3
2013 2
2014 3
2015 5
2016 3
2017 5
2018 4
2019 6
2020 12
2021 13
2022 11
2023 16
2024 16
2025 19
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for M. mohseni
Your search for M. Mohiseni retrieved no results
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
Adults (aged 18 years) with a body-mass index (BMI) of 27 kg/m(2) or higher and glycated haemoglobin (HbA(1c)) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive …
Adults (aged 18 years) with a body-mass index (BMI) of 27 kg/m(2) or higher and glycated haemoglobin (HbA(1c)) of 7-10% (53-86 mmol/ …
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
J. Hodiamont, N. P. Juffermans, J. M. Janssen, C. S. Bouman, R. A. Mathot, M. D. De Jong, R. M. Van Hest P106 - Systematic review of cefepime induced neurotoxicity L. ...Honzawa, H. Yasuda, T. Adati, S. Suzaki, M. Horibe, M. Sasaki, M. Sa …
J. Hodiamont, N. P. Juffermans, J. M. Janssen, C. S. Bouman, R. A. Mathot, M. D. De Jong, R. M. Van Hest P106 - Systema …
Key Considerations When Targeting a Heel Spur.
Mohseni M, Mousavi E, Alebouyeh MR. Mohseni M, et al. Anesth Pain Med. 2023 Oct 1;13(5):e139326. doi: 10.5812/aapm-139326. eCollection 2023 Oct. Anesth Pain Med. 2023. PMID: 38659999 Free PMC article. Review.
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Gawrieh S, et al. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. Hepatology. 2021. PMID: 33811367 Free article. Clinical Trial.
APPROACH AND RESULTS: A total of 106 patients with NAFLD/NASH with alanine aminotransferase (ALT) 50 U/L at baseline and body mass index 25 kg/m(2) were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. ...
APPROACH AND RESULTS: A total of 106 patients with NAFLD/NASH with alanine aminotransferase (ALT) 50 U/L at baseline and body mass index …
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Disease and Injury and Risk Factor Collaborators. GBD 2023 Disease and Injury and Risk Factor Collaborators. Lancet. 2025 Oct 18;406(10513):1873-1922. doi: 10.1016/S0140-6736(25)01637-X. Epub 2025 Oct 12. Lancet. 2025. PMID: 41092926 Free PMC article.
118 results